AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04566120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorohexidine based mouthwash
Description: chlorohexidine based mouthwash
Study NCT06114186 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FAM intervention consisting of a Follower of glucose data, Action Plan, and Remote Monitoring of glucose data
Description: using remote monitoring and real-time glucose data sharing with a Follower.
Study NCT06114186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard of care
Description: self reported HbA1C or GMI
Study NCT05277558 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Investigators are observing brain health over time (21 months) in these groups
Study NCT06465004 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Consumption of protein - rich drink
Description: The participants will drink on of three protein - rich drinks
Study NCT05612113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Live Supervision + Session Goal Formulation
Description: Read under Arms
Study NCT05612113 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Session Goal Formulation
Description: Read under Arms
Study NCT05587907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitLight Trainer
Description: Evaluation of the reaction time before and after special training program using visual stimuli.
Study NCT05667740 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gamma-PN3
Description: Inactivated whole-cell pneumococcal vaccine
Study NCT05667740 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar-13
Description: Licensed polysaccharide conjugate pneumococcal vaccine
Study NCT05667740 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax-23
Description: Licensed polysaccharide pneumococcal vaccine
Study NCT05667740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT06375317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-L1 inhibitor: Adebrelimab Injection；Regorafenib Tablets
Description: PD-L1 injection: 20 mg/kg, administered every 3 weeks (Q3W).~Regorafenib: 80 mg, orally, once daily (qd), continuously for 14 days per cycle, followed by a 7-day rest period, administered every 3 weeks (Q3W).~FOLFOX regimen: Oxaliplatin 85 mg/m2, Calcium folinate 400 mg/m2, Fluorouracil 400 mg/m2 as an IV bolus, followed by Fluorouracil 1200 mg/m2 infusion over 23 hours, administered every 3 weeks (Q3W) for a total of 6 cycles.~The above doses are recommended doses.
Study NCT04891497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl Fumarate
Description: Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
Study NCT04891497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 240mg orally twice daily for 3 consecutive days
Study NCT06165042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glass hybrid restorative system
Description: In the teeth where the indication is identified, selective caries removal will be performed to eliminate the decayed tooth tissue. Subsequently, for each patient in the study apply glass hybrid restorative system (Equia Forte, GC Europe, Leuven, Belgium)
Study NCT06165042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoride varnish + Glass hybrid restorative system
Description: In the teeth where the indication is identified, selective caries removal will be performed to eliminate the decayed tooth tissue. Subsequently, for each patient in the study apply Fluoride varnish (SDI Riva Star)+ Glass hybrid restorative (Equia Forte, GC Europe, Leuven, Belgium)
Study NCT04728386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: curcumin solution
Description: 2 % curcumin solution as root canal irrigant
Study NCT04728386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sodium hypochlorite
Description: 2.5% sodium hypochlorite solution as root canal irrigant
Study NCT04891380 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LUCAS 2 Active Decompression 2
Description: Chest compression with active decompression of the chest. Measurement of physiological parameters.
Study NCT04891380 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hypotension
Description: measurement of physiological parameters
Study NCT04891380 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intensive care transport
Description: Measurement of physiological parameters
Study NCT05357027 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TC-E202 cells
Description: T cells genetically engineered with a TCR targeting HPV16 E6 (E6 TCR) that display specific reactivity against HLA-A2+, HPV-16+ target cells
Study NCT05357027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Following cell infusion, the patient receives high-dose bolus IL-2, which is dosed to individual patient tolerance. IL-2 improves the survival of TC-E202 cells after infusion.
Study NCT05357027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.
Study NCT05357027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide Capsules
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.
Study NCT04184609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: In this condition, the participants will not receive any medications or drugs before exercise
Study NCT05720390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quinine
Description: Quinine, which is a bitter compound, extracted from the bark of the cinchona tree and has been shown in our previous studies to lower blood glucose in doses of 300-600 mg, will be 'active' in this condition.
Study NCT05720390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: L-leucine
Description: L-leucine, which is a branched-chain amino acid, and one of the building blocks of protein, therefore is part of our daily diet, will be 'active' in this condition.
Study NCT05720390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combination of quinine and L-leucine
Description: In this condition, both quinine and L-leucine will be administered as 'active'.
Study NCT05720390 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: In the condition, where quinine is 'active', control for L-leucine (5 ml oraplus and 95 ml saline) will be administered. In the condition, where L-leucine will be 'active', control for quinine (10 ml distilled water) will be administered.
Study NCT05720390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: In the condition, where quinine is 'active', control for L-leucine (5 ml oraplus and 95 ml saline) will be administered. In the condition, where L-leucine will be 'active', control for quinine (10 ml distilled water) will be administered.
Study NCT05948631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MISC intervention
Description: MISC is a semi-structured, participatory caregiver intervention following these steps: (1) Identify the mother's personal and cultural characteristics, which include a respectful discussion around the mother's child-rearing views, objectives, needs and expectations. (2) Create a baseline through videotaped interactions. (3) Create caregivers' personal interaction profile on the basis of videotaped interaction. The caseworker builds on the initial videotaped interaction and uses subsequent bi-weekly videotaped interactions to give feedback to mothers on the frequency of mediational behaviors thereby quantifying the quality of mother-child interactions. Interactional characteristics are jointly identified and conceptualized according to MISC principles. The mother learns to understand both her own and the child's behavior within a meaningful framework, enhancing reflection of caregiving practices. (4) In-service training (once a month). (5) Re-evaluate training efficacy.
Study NCT05948631 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: TAU consists of supportive services including trauma informed, client-centered, and strength-based case management and advocacy. All services are focused on the mother and do not include any child-focused intervention. Instead, staff provide in-home intensive case management services to assess and provide safety planning, assess other social service needs, link abused mothers to community resources, and assist clients in rehousing. TAU direct contact with the mother consists of bi-weekly contact, which matches the contact frequency for the intervention group. However, MISC mothers will be receiving TAU+MISC-IPV (2 hours bi-weekly contact) compared with TAU only (30 minutes biweekly contact).
Study NCT04759157 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples-based treatment
Description: Couples will attend 3, video based sessions for couples-based treatment
Study NCT04184609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: 180 mcg of Albuterol will be administered before exercise
Study NCT06255132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated pupillometer NPi-200
Description: Pupillary variables in both eyes are recorded and measured with NPi-200 every 30 minutes from the induction of anesthesia. At the end of the surgery, the patient is transferred to the intensive care unit (ICU), and the pupillary variables are recorded until the patient regains consciousness (Richmond agitation sedation scale, RASS>-3). Specific hemodynamic, respiratory, surgical, and EBP data are also recorded as well as NIRS variables.~As soon as the patient had regained consciousness (RASS > 3), they were assessed for delirium for a total period of five days. Nursing and/or medical staff administered the CAM-ICU score to patients twice a day (morning and afternoon).
Study NCT04759157 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized education
Description: Patients will receive standardized educational materials
Study NCT04847427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core exercises training
Description: Participants will perform:~1. Squats, 4 sets of 5 repetitions at 60% 1RM~2. Deadlifts, 4 sets of 5 repetitions at 60% 1RM~3. Lunges, 4 sets of 5 repetitions at 60% 1RM~4. Step ups, 4 sets of 5 repetitions at 60% 1RM
Study NCT04847427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structural exercises training
Description: Participants will perform:~1. Snatch, 4 sets of 5 repetitions at 60% 1RM~2. Hang clean, 4 sets of 5 repetitions at 60% 1RM~3. Push jerk, 4 sets of 5 repetitions at 60% 1RM~4. Split push jerk, 4 sets of 5 repetitions at 60% 1RM
Study NCT04847427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accentuated eccentric exercises training
Description: Participants will perform:~1. Deadlifts - squat jump, 4 sets of 5 repetitions at 30% body mass (BM)~2. Step down - squat jump, 4 sets of 5 repetitions at 30% BM~3. Step down - lunges, 4 sets of 5 repetitions at 30% BM~4. Bulgarian squat jumps, 4 sets of 5 repetitions at 30% BM
Study NCT04847427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control trial
Description: Participants will perform all the measurements that are comprised in the experimental conditions without performing any exercise protocol
Study NCT05480852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bis-GMA Free dental resin composite
Description: Restorative Material
Study NCT05480852 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bis-GMA Free dental resin composite
Description: Restorative Material
Study NCT01952873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolonged inflation
Description: Prolonged inflation will be performed at high pressure(16 atm)and maintained for 30 sec with \<0.3 atm drop during that period.
Study NCT01952873 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rapid inflation
Description: The rapid inflation method will consist of reaching an operator determined high-pressure (16 atm) with the stent-deployment balloon and maintaining it the duration of time determined by the operator but \<30 sec if the balloon is fully inflated and longer only if the balloon requires a longer duration to become fully inflated.
Study NCT04948606 — intervention group
Intervention type: DRUG
Intervention: Diroximel Fumarate
Description: Administered as specified in the treatment arm.
Study NCT06010576 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided rendezvous
Description: A linear array echoendoscope would be used to evaluate the common bile duct and left intrahepatic duct in order to identify the optimal route for biliary access by fine needle. Using a 19 gauge EUS needle, the dilated biliary tree will be accessed by either a transduodenal puncture to the common bile duct or a transgastric puncture to the left intrahepatic duct under direct EUS guidance. The optimal access route will be based on patient's anatomy after EUS assessment and left to the discretion of the investigator. Next, a guidewire would be advanced through the needle into the bile duct and out of the papillary orifice. The echoendoscope would then be exchanged to a duodenoscope for ERCP. The EUS rendezvous ERCP procedure will be completed by retrieving the rendezvous guidewire into the duodenoscope or by cannulation alongside the rendezvous guidewire to obtain biliary access.
Study NCT06010576 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early precut papillotomy group
Description: The precut papillotomy would be performed with 1 of the following acceptable techniques per the usual practice of the study investigator and institution: 1) conventional precut papillotomy by needle knife, 2) precut fistulotomy by needle knife, or 3) transpancreatic precut papillotomy by papillotome
Study NCT05296603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI-322 Plus Lenvatinib
Description: IBI322 is based on the 3+3 model, with a dose ascent starting from 10mg
Study NCT05857150 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Treadmill Test
Description: Measurement of whole-body fitness level. Walking or running on a treadmill and breathing into a machine that measures oxygen level during test. Heart rhythm is continuously monitored during exercise using an electrocardiogram (ECG).
Study NCT05846620 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchoalveolar lavage
Description: Bronchoalveolar lavage in the middle lobe of the right lung and a mini-bronchoalveolar lavage in the upper and lower lobe of the right lung
Study NCT05857150 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Strength Test
Description: Measure the strength of leg muscles by kicking against a machine with resistance.
Study NCT05857150 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dual-Energy X-Ray Absorptiometry
Description: Body composition measurement.
Study NCT05857150 — intervention group
Intervention type: PROCEDURE
Intervention: Muscle Biopsy
Description: Obtain a small piece of muscles from the upper part of the legs
Study NCT05857150 — intervention group
Intervention type: PROCEDURE
Intervention: Fat Biopsy
Description: Fat sample taken from abdomen
Study NCT05857150 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Resting Energy Expenditure
Description: Measured by indirect calorimetry. Measures how much energy the body uses at rest by placing a special plastic dome over the head while resting quietly for 30 minutes. Measures oxygen breathed in and carbon dioxide breathed out.
Study NCT05857150 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: MRI on upper leg to look at fat and muscle
Study NCT05778461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-ornithine L-Aspartate
Description: LOLA will be administered via continuous intravenous infusion at a dosage of 0.75g/kg/day for 72h (maximum 30g/day). High volume plasma exchange (2x plasma volume) will be started at least 8 hours after initiation of LOLA, and will be completed within 4-5 hours depending on the volume of exchange. Three consecutive cycles of HVPE will be performed, starting at 8h, 32h and 56h respectively.
Study NCT05778461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered via continuous infusion for 72h, along with HVPE (2x plasma volume) starting at 8h, 32h and 56h respectively.
Study NCT01101412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edetate Calcium Disodium
Description: Given through CVC or PVC.
Study NCT01101412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Given through CVC or PVC
Study NCT01101412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Description: Given through CVC or PVC
Study NCT01101412 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic Saline
Description: Given through CVC or PVC
Study NCT05457777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interview in digital game addiction
Description: Motivational interviewing, which is a technique developed by William Miller that aims to change behavior by revealing the contradiction of problematic behavior with the value judgments of the person and creating motivation by the counselor, will be applied to the individuals with digital game addiction.
Study NCT06033131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin ER
Description: Metformin ER, one gram three times daily taken orally. Once the participants have been recruited, they will start by taking one 500 mg tablet three times a day. If well tolerated it will be increased day two to a maximum of two tablets three times a day. Treatment will continue until delivery. If there are side effects that are not tolerable, the dose will be decreased and the participant will remain blinded. Each participant will keep a treatment diary and number of tablets taken will be documented by the participant or hospital staff. The study will not alter or interfere with treatment or care routinely given for preterm preeclampsia.
Study NCT06033131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, two tablets three times daily taken orally. Once the participants have been recruited, they will start by taking one tablet three times a day. If well tolerated it will be increased day two to a maximum of two tablets three times a day. Treatment will continue until delivery. If there are side effects that are not tolerable, the dose will be decreased and the participant will remain blinded. Each participant will keep a treatment diary and number of tablets taken will be documented by the participant or hospital staff. The study will not alter or interfere with treatment or care routinely given for preterm preeclampsia.
Study NCT06544226 — intervention group
Intervention type: DEVICE
Intervention: UH100
Description: This is a non-interventional pilot study. Given the within-subject and longitudinal design used in this study, traditional intervention settings are not applicable. All participants will receive weekly and tri-point assessments,~* Weekly (twice per week) Assessments: Physical vitals such as BMI, Blood Pressure, Heart Rate~* Weekly (once per week) Assessments: Sit-Up-Squat-Stand Test, Video diary entries, GAD-7, and PHQ-9.~* Tri-point (week 1, 8, 6) assessments: EDE-Q, Patient Acceptance Questionnaire and the Food-specific Stop Signal Task.
Study NCT06506630 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: coenzyme Q10
Description: 300 mg capsule twice a day
Study NCT06506630 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 300 mg capsule twice a day
Study NCT04345952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calm Meditation Mobile App
Description: The Calm Meditation Mobile App will be used to deliver the meditation intervention to study participants. The Calm app is downloaded onto the participant's smartphone.
Study NCT05083975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy System
Description: Vibrating Device
Study NCT05083975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical anesthetic
Description: 20% benzocaine gel (Opahl Topical Gel)
Study NCT05083975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.8 ml of 4% articaine hydrochloride with epinephrine 1:100,000
Description: Local dental anesthetic agent
Study NCT05083975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.8 ml of 4% articaine hydrochloride with epinephrine 1:100,000
Description: Local dental anesthetic agent
Study NCT05223504 — intervention group
Intervention type: DEVICE
Intervention: Continuously monitoring
Description: Included patients are monitored with WARD equipment during the last part of hospitalization and the first days after discharge. Monitoring will last for a maximum of eight days.
Study NCT05908279 — intervention group
Intervention type: OTHER
Intervention: Walking test
Description: Walk with and without a metronome
Study NCT05908279 — intervention group
Intervention type: OTHER
Intervention: Disease assessement
Description: Disease stage assessed by a doctor
Study NCT05363735 — intervention group
Intervention type: OTHER
Intervention: Ultrasound Elastography
Description: Patients will be examined by ultrasound elastography.
Study NCT06479850 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KF-STRIDE®
Description: Treatment group will receive 12 web based sessions of a strength-based training tool (once or twice a week). Sessions are approximately 60 minutes long.
Study NCT05040282 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Implanon NXT
Description: women will be subjected to etonogestrel 68 mg implant insertion. Participants will be trained on how to fill the menstrual diary. The menstrual diary includes information about days of bleeding and spotting days.